Adaptive Radiation Boost for Rectal Cancer (ARBOR) - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.

  • By

  • September 4, 2026

  • 3 min

Share

Clinical Report: Adaptive Radiation Boost for Rectal Cancer (ARBOR)

Overview

The ARBOR trial investigates the safety and efficacy of adaptive radiation therapy following standard chemoradiation in rectal cancer patients.

Background

Rectal cancer remains a significant clinical challenge, particularly in locally advanced cases. The integration of adaptive radiation therapy may offer a novel approach to personalize radiation delivery based on tumor response.

Data Highlights

No numerical data available in the provided source material.

Key Findings

  • The ARBOR trial aims to assess the safety and efficacy of adaptive radiation therapy after standard chemoradiation.
  • Participants will receive standard radiation and chemotherapy before additional adaptive radiation based on MRI assessments.
  • Inclusion criteria focus on patients with histologically confirmed rectal adenocarcinoma and specific staging parameters.
  • Exclusion criteria include prior treatments for rectal cancer and uncontrolled intercurrent illnesses.
  • Translation services will be provided to enhance diversity in patient inclusion.

Clinical Implications

Clinicians should consider the eligibility criteria when evaluating patients for participation in such trials.

Conclusion

The ARBOR trial explores adaptive radiation therapy in rectal cancer treatment.

Related Resources & Content

  1. NCI, ClinicalTrials.gov, 2025 -- Adaptive Radiation Therapy Boost for the Treatment of Rectal Cancer, The ARBOR Trial
  2. fox chase cancer center — Adaptive Radiation for Abdominopelvic Metastases (ARAM) - Clinical Trial
  3. The ASCO Post — Rectal Cancer: AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
  4. fox chase cancer center — Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
  5. Techniques in Coloproctology — Factors such as advanced age, neural and extramural vascular invasion, along with short-course radiotherapy, correlate with reduced tumor regression in locally advanced rectal cancer: a retrospective cohort analysis
  6. Adaptive Radiation for Abdominopelvic Metastases (ARAM) - Clinical Trial
  7. Rectal Cancer: AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
  8. Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)
  9. Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update - PubMed
  10. Management of Locally Advanced Rectal Cancer: ASCO Guideline
  11. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
  12. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial - PubMed
  13. Efficacy and safety of MR-guided adaptive simultaneous integrated boost radiotherapy to primary lesions and positive lymph nodes in the neoadjuvant treatment of locally advanced rectal cancer: a randomized controlled phase III trial - PMC
  14. Safety and early organ preservation outcomes after dose escalation with MR-guided radiotherapy for rectal cancer (preRADAR): A phase I trial - PMC
  15. Adaptive Radiation Therapy Boost for the Treatment of Rectal Cancer, The ARBOR Trial - NCI
  16. Quality and Safety Considerations for Adaptive Radiation Therapy: An ASTRO White Paper - PubMed

Original Source(s)

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

  • by

  • September 4, 2026

Related Content

Therapy-induced immunoediting and the evolution of cancer immune escape

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Fellowship-Trained Neuro-Oncologist Nishika Karbhari, M.D., Joins Baptist Health Herbert Wertheim Cancer Institute

Fellowship-trained neuro-oncologist Nishika Karbhari, M.D., has joined Baptist Health Herbert Wertheim Cancer Institute.

  • by

  • September 3, 2026

  • 2 min